Jeny Shklover
Research Subjects
Research Interests
Jeny Shklover has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Avi Schroeder
The Louis Family Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies Department of Chemical Engineering Technion – Israel Institute of Technology Haifa 32000 Israel
10 shared publications Janna Shainsky-Roitman
The Louis Family Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion, Haifa, Israel
6 shared publications- Estee Kurant
Department of Genetics and Developmental Biology, The Rappaport Family Institute for Research in the Medical Sciences, Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 31096, Israel
5 shared publications - Michael Fry
Department of Biochemistry, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel
4 shared publications Nitzan Krinsky
Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion - Israel Institute of Technology
4 shared publicationsOmer Adir
Department of Biological Engineering
4 shared publications
Latest Publications
- Open Access
- 18 June 2026
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
- Vol. 15 (7) , 2823-2836
Phosphoserine as an Alternative Energy Source for E. coli Cell-Free Protein Synthesis with Increased Yield and Prolonged Activity
Energy-supplying molecules are essential for biological processes, particularly for transcription and translation. Cell-free protein synthesis (CFPS) systems are powerful tools for in vitro protein production, offering flexibility for applications ranging from high-throughput protein screening to therapeutic protein production. However, energy regeneration in CFPS remains a key challenge, particularly for large-scale or resource-constrained settings. In this study, we introduce phosphoserine (PS) as a simple, cost-effective alternative secondary energy source, capable of partially or fully replacing 3-phosphoglycerate (PGA), the commonly used energy donor in E. coli lysate-based CFPS, whose availability is often limited. By supplementing CFPS reactions with PS, we demonstrate significant improvements in protein yield and cost-efficiency, achieving a 2-fold increase in protein production. Importantly, PS enhancement is maintained across lysate batches and protein targets. Furthermore, we offer affordable CFPS compositions that retain protein synthesis, making the system more accessible for resource-limited settings. Additionally, we show that higher PS concentrations, while reducing final protein yield, extend the reaction duration by more than 2-fold. Therefore, the incorporation of PS as an alternative energy donor enables a tunable modality for balancing protein yield, reaction longevity, and cost. Our data support a model in which PS enhances CFPS via the serine biosynthesis pathway by modulating flux between serine production and glycolysis to support ATP regeneration. Lastly, we validate the use of these optimized CFPS compositions within synthetic cells (SCs). This study establishes PS as a promising energy source for E. coli lysate-based CFPS systems, paving the way for enhanced and economical protein synthesis platforms tailored to diverse clinical, biotechnological, and industrial needs.
- 18 June 2026
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
- Vol. 15 (7) , 2823-2836
Open AccessPhosphoserine as an Alternative Energy Source for E. coli Cell-Free Protein Synthesis with Increased Yield and Prolonged Activity
Energy-supplying molecules are essential for biological processes, particularly for transcription and translation. Cell-free protein synthesis (CFPS) systems are powerful tools for in vitro protein production, offering flexibility for applications ranging from high-throughput protein screening to therapeutic protein production. However, energy regeneration in CFPS remains a key challenge, particularly for large-scale or resource-constrained settings. In this study, we introduce phosphoserine (PS) as a simple, cost-effective alternative secondary energy source, capable of partially or fully replacing 3-phosphoglycerate (PGA), the commonly used energy donor in E. coli lysate-based CFPS, whose availability is often limited. By supplementing CFPS reactions with PS, we demonstrate significant improvements in protein yield and cost-efficiency, achieving a 2-fold increase in protein production. Importantly, PS enhancement is maintained across lysate batches and protein targets. Furthermore, we offer affordable CFPS compositions that retain protein synthesis, making the system more accessible for resource-limited settings. Additionally, we show that higher PS concentrations, while reducing final protein yield, extend the reaction duration by more than 2-fold. Therefore, the incorporation of PS as an alternative energy donor enables a tunable modality for balancing protein yield, reaction longevity, and cost. Our data support a model in which PS enhances CFPS via the serine biosynthesis pathway by modulating flux between serine production and glycolysis to support ATP regeneration. Lastly, we validate the use of these optimized CFPS compositions within synthetic cells (SCs). This study establishes PS as a promising energy source for E. coli lysate-based CFPS systems, paving the way for enhanced and economical protein synthesis platforms tailored to diverse clinical, biotechnological, and industrial needs.
- Top Cited PapersOpen Access
- 16 September 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (41) , 36106-36128
AI-Validated Brain Targeted mRNA Lipid Nanoparticles with Neuronal Tropism
Targeting therapeutic nanoparticles to the brain poses a challenge due to the restrictive nature of the blood-brain barrier (BBB). Here we report the development of mRNA-loaded lipid nanoparticles (LNPs) functionalized with BBB-interacting small molecules, thereby enhancing brain delivery and gene expression. Screening brain-targeted mRNA-LNPs in central nervous system (CNS) in vitro models and through intravenous administration in mice demonstrated that acetylcholine-conjugated LNPs achieved superior brain tropism and gene expression, outperforming LNP modifications with nicotine, glucose, memantine, cocaine, tryptophan, and other small molecules. An artificial intelligence (AI)-based model designed to predict the BBB permeability of small-molecule ligands showed strong alignment with our experimental results, providing in vivo validation of its predictive capacity. Cell-specific biodistribution analysis in Cre-reporter Ai9 mice showed that acetylcholine-functionalized LNPs preferentially transfected neurons and astrocytes following either intravenous or intracerebral administration. Mechanistic studies suggest that acetylcholine-LNP uptake is mediated by the functional engagement of acetylcholine receptors (AchRs) followed by endocytosis, which synergistically enhances intracellular mRNA delivery. Moreover, acetylcholine-LNPs successfully crossed a human BBB-on-a-chip model, enabling transgene expression in human iPSC-derived neurons. Their effective penetration and transfection in human brain organoids further support their potential activity in human-based systems. These findings establish a predictive and modular framework for engineering CNS-targeted LNPs, advancing precision gene delivery for brain disorders.
- 16 September 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (41) , 36106-36128
Top Cited PapersOpen AccessAI-Validated Brain Targeted mRNA Lipid Nanoparticles with Neuronal Tropism
Targeting therapeutic nanoparticles to the brain poses a challenge due to the restrictive nature of the blood-brain barrier (BBB). Here we report the development of mRNA-loaded lipid nanoparticles (LNPs) functionalized with BBB-interacting small molecules, thereby enhancing brain delivery and gene expression. Screening brain-targeted mRNA-LNPs in central nervous system (CNS) in vitro models and through intravenous administration in mice demonstrated that acetylcholine-conjugated LNPs achieved superior brain tropism and gene expression, outperforming LNP modifications with nicotine, glucose, memantine, cocaine, tryptophan, and other small molecules. An artificial intelligence (AI)-based model designed to predict the BBB permeability of small-molecule ligands showed strong alignment with our experimental results, providing in vivo validation of its predictive capacity. Cell-specific biodistribution analysis in Cre-reporter Ai9 mice showed that acetylcholine-functionalized LNPs preferentially transfected neurons and astrocytes following either intravenous or intracerebral administration. Mechanistic studies suggest that acetylcholine-LNP uptake is mediated by the functional engagement of acetylcholine receptors (AchRs) followed by endocytosis, which synergistically enhances intracellular mRNA delivery. Moreover, acetylcholine-LNPs successfully crossed a human BBB-on-a-chip model, enabling transgene expression in human iPSC-derived neurons. Their effective penetration and transfection in human brain organoids further support their potential activity in human-based systems. These findings establish a predictive and modular framework for engineering CNS-targeted LNPs, advancing precision gene delivery for brain disorders.
- Open Access
- 28 April 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-13
Synthetic cells with self-activating optogenetic proteins communicate with natural cells
Development of regulated cellular processes and signaling methods in synthetic cells is essential for their integration with living materials. Light is an attractive tool to achieve this, but the limited penetration depth into tissue of visible light restricts its usability for in-vivo applications. Here, we describe the design and implementation of bioluminescent intercellular and intracellular signaling mechanisms in synthetic cells, dismissing the need for an external light source. First, we engineer light generating SCs with an optimized lipid membrane and internal composition, to maximize luciferase expression levels and enable high-intensity emission. Next, we show these cells’ capacity to trigger bioprocesses in natural cells by initiating asexual sporulation of dark-grown mycelial cells of the fungus Trichoderma atroviride. Finally, we demonstrate regulated transcription and membrane recruitment in synthetic cells using bioluminescent intracellular signaling with self-activating fusion proteins. These functionalities pave the way for deploying synthetic cells as embeddable microscale light sources that are capable of controlling engineered processes inside tissues.
- 28 April 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-13
Open AccessSynthetic cells with self-activating optogenetic proteins communicate with natural cells
Development of regulated cellular processes and signaling methods in synthetic cells is essential for their integration with living materials. Light is an attractive tool to achieve this, but the limited penetration depth into tissue of visible light restricts its usability for in-vivo applications. Here, we describe the design and implementation of bioluminescent intercellular and intracellular signaling mechanisms in synthetic cells, dismissing the need for an external light source. First, we engineer light generating SCs with an optimized lipid membrane and internal composition, to maximize luciferase expression levels and enable high-intensity emission. Next, we show these cells’ capacity to trigger bioprocesses in natural cells by initiating asexual sporulation of dark-grown mycelial cells of the fungus Trichoderma atroviride. Finally, we demonstrate regulated transcription and membrane recruitment in synthetic cells using bioluminescent intracellular signaling with self-activating fusion proteins. These functionalities pave the way for deploying synthetic cells as embeddable microscale light sources that are capable of controlling engineered processes inside tissues.
- Open Access
- 8 October 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (41)
Targeting neurons in the tumor microenvironment with bupivacaine nanoparticles reduces breast cancer progression and metastases
Targeting neurons in breast cancer with anesthetic nanoparticles inhibits nerve-cancer stimulation and tumor progression.
- 8 October 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (41)
Open AccessTargeting neurons in the tumor microenvironment with bupivacaine nanoparticles reduces breast cancer progression and metastases
Targeting neurons in breast cancer with anesthetic nanoparticles inhibits nerve-cancer stimulation and tumor progression.
- Open Access
Bioluminescent Synthetic Cells Communicate with Natural Cells and Self-Activate Light-Responsive Proteins
Development of regulated cellular processes and signaling methods in synthetic cells is essential for their integration with living materials. Light is an attractive tool to achieve this, but the limited penetration depth into tissue of visible light restricts its usability for in-vivo applications. Here, we describe the synthesis and application of blue-light-generating synthetic cells using bioluminescence, dismissing the need for an external light source. First, the lipid membrane and internal composition of light-producing synthetic cells were optimized to enable high-intensity emission. Next, we show these cells’ capacity for triggering bioprocesses in natural cells by initiating asexual sporulation of dark-grown mycelial cells of the fungus Trichoderma atroviride in a quorum-sensing like mechanism. Finally, we demonstrate regulated transcription and membrane recruitment in synthetic cells using bioluminescent self-activating fusion proteins. These functionalities pave the way for deploying synthetic cells as embeddable microscale light sources that are capable of activating engineered processes inside tissues.
Open AccessBioluminescent Synthetic Cells Communicate with Natural Cells and Self-Activate Light-Responsive Proteins
Development of regulated cellular processes and signaling methods in synthetic cells is essential for their integration with living materials. Light is an attractive tool to achieve this, but the limited penetration depth into tissue of visible light restricts its usability for in-vivo applications. Here, we describe the synthesis and application of blue-light-generating synthetic cells using bioluminescence, dismissing the need for an external light source. First, the lipid membrane and internal composition of light-producing synthetic cells were optimized to enable high-intensity emission. Next, we show these cells’ capacity for triggering bioprocesses in natural cells by initiating asexual sporulation of dark-grown mycelial cells of the fungus Trichoderma atroviride in a quorum-sensing like mechanism. Finally, we demonstrate regulated transcription and membrane recruitment in synthetic cells using bioluminescent self-activating fusion proteins. These functionalities pave the way for deploying synthetic cells as embeddable microscale light sources that are capable of activating engineered processes inside tissues.
- Open Access
Chemotherapeutic Nanoparticles Accumulate in the Female Reproductive System during Ovulation Affecting Fertility and Anticancer Activity
Throughout the female menstrual cycle, physiological changes occur that affect the biodistribution of nanoparticles within the reproductive system. This can have positive or negative effects. We demonstrate a 2-fold increase in nanoparticle accumulation in the ovaries during female mouse ovulation compared to the non-ovulatory stage following intravenous administration. Accumulation in the reproductive system is favored by nanoparticles smaller than 100 nm. Chemotherapeutic nanoparticles administered during ovulation increased ovarian toxicity and decreased short-term and long-term fertility when compared to the free drug. Breast cancer treated with nanomedicines during ovulation results in higher drug accumulation in the reproductive system rather than at the site of the tumor, reducing treatment efficacy. Conversely, ovarian cancer treatment was improved by enhanced nanoparticle accumulation in the ovaries during ovulation. Our findings suggest that the menstrual cycle should be considered when designing and implementing nanotherapeutics for females.
Open AccessChemotherapeutic Nanoparticles Accumulate in the Female Reproductive System during Ovulation Affecting Fertility and Anticancer Activity
Throughout the female menstrual cycle, physiological changes occur that affect the biodistribution of nanoparticles within the reproductive system. This can have positive or negative effects. We demonstrate a 2-fold increase in nanoparticle accumulation in the ovaries during female mouse ovulation compared to the non-ovulatory stage following intravenous administration. Accumulation in the reproductive system is favored by nanoparticles smaller than 100 nm. Chemotherapeutic nanoparticles administered during ovulation increased ovarian toxicity and decreased short-term and long-term fertility when compared to the free drug. Breast cancer treated with nanomedicines during ovulation results in higher drug accumulation in the reproductive system rather than at the site of the tumor, reducing treatment efficacy. Conversely, ovarian cancer treatment was improved by enhanced nanoparticle accumulation in the ovaries during ovulation. Our findings suggest that the menstrual cycle should be considered when designing and implementing nanotherapeutics for females.
- 27 April 2020
- Published by MyJove Corporation in Journal of Visualized Experiments
- Vol. 158 (158) , e60829
Preparing Protein Producing Synthetic Cells using Cell Free Bacterial Extracts, Liposomes and Emulsion Transfer
The bottom-up assembly approach for construction of synthetic cells is an effective tool for isolating and investigating cellular processes in a cell mimicking environment. Furthermore, the development of cell-free expression systems has demonstrated the ability to reconstitute the protein production, transcription and translation processes (DNA→RNA→protein) in a controlled manner, harnessing synthetic biology. Here we describe a protocol for preparing a cell-free expression system, including the production of a potent bacterial lysate and encapsulating this lysate inside cholesterol-rich lipid-based giant unilamellar vesicles (GUVs) (i.e., stable liposomes), to form synthetic cells. The protocol describes the methods for preparing the components of the synthetic cells including the production of active bacterial lysates, followed by a detailed step-by-step preparation of the synthetic cells based on a water-in-oil emulsion transfer method. These facilitate the production of millions of synthetic cells in a simple and affordable manner with a high versatility for producing different types of proteins. The obtained synthetic cells can be used to investigate protein/RNA production and activity in an isolated environment, in directed evolution, and also as a controlled drug delivery platform for on-demand production of therapeutic proteins inside the body.
- 27 April 2020
- Published by MyJove Corporation in Journal of Visualized Experiments
- Vol. 158 (158) , e60829
Preparing Protein Producing Synthetic Cells using Cell Free Bacterial Extracts, Liposomes and Emulsion Transfer
The bottom-up assembly approach for construction of synthetic cells is an effective tool for isolating and investigating cellular processes in a cell mimicking environment. Furthermore, the development of cell-free expression systems has demonstrated the ability to reconstitute the protein production, transcription and translation processes (DNA→RNA→protein) in a controlled manner, harnessing synthetic biology. Here we describe a protocol for preparing a cell-free expression system, including the production of a potent bacterial lysate and encapsulating this lysate inside cholesterol-rich lipid-based giant unilamellar vesicles (GUVs) (i.e., stable liposomes), to form synthetic cells. The protocol describes the methods for preparing the components of the synthetic cells including the production of active bacterial lysates, followed by a detailed step-by-step preparation of the synthetic cells based on a water-in-oil emulsion transfer method. These facilitate the production of millions of synthetic cells in a simple and affordable manner with a high versatility for producing different types of proteins. The obtained synthetic cells can be used to investigate protein/RNA production and activity in an isolated environment, in directed evolution, and also as a controlled drug delivery platform for on-demand production of therapeutic proteins inside the body.
- Open Access
- 13 November 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-12
Bovine pericardial extracellular matrix niche modulates human aortic endothelial cell phenotype and function
Xenogeneic biomaterials contain biologically relevant extracellular matrix (ECM) composition and organization, making them potentially ideal surgical grafts and tissue engineering scaffolds. Defining the effect of ECM niche (e.g., basement membrane vs. non-basement membrane) on repopulating cell phenotype and function has important implications for use of xenogeneic biomaterials, particularly in vascular applications. We aim to understand how serous (i.e., basement membrane) versus fibrous (i.e., non-basement membrane) ECM niche of antigen-removed bovine pericardium (AR-BP) scaffolds influence human aortic endothelial cell (hAEC) adhesion, growth, phenotype, inflammatory response and laminin production. At low and moderate seeding densities hAEC proliferation was significantly increased on the serous side. Similarly, ECM niche modulated cellular morphology, with serous side seeding resulting in a more rounded aspect ratio and intact endothelial layer formation. At moderate seeding densities, hAEC production of human laminin was enhanced following serous seeding. Finally, inflammatory marker and pro-inflammatory cytokine expression decreased following long-term cell growth regardless of seeding side. This work demonstrates that at low and moderate seeding densities AR-BP sidedness significantly impacts endothelial cell growth, morphology, human laminin production, and inflammatory state. These findings suggest that ECM niche has a role in modulating response of repopulating recipient cells toward AR-BP scaffolds for vascular applications.
- 13 November 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-12
Open AccessBovine pericardial extracellular matrix niche modulates human aortic endothelial cell phenotype and function
Xenogeneic biomaterials contain biologically relevant extracellular matrix (ECM) composition and organization, making them potentially ideal surgical grafts and tissue engineering scaffolds. Defining the effect of ECM niche (e.g., basement membrane vs. non-basement membrane) on repopulating cell phenotype and function has important implications for use of xenogeneic biomaterials, particularly in vascular applications. We aim to understand how serous (i.e., basement membrane) versus fibrous (i.e., non-basement membrane) ECM niche of antigen-removed bovine pericardium (AR-BP) scaffolds influence human aortic endothelial cell (hAEC) adhesion, growth, phenotype, inflammatory response and laminin production. At low and moderate seeding densities hAEC proliferation was significantly increased on the serous side. Similarly, ECM niche modulated cellular morphology, with serous side seeding resulting in a more rounded aspect ratio and intact endothelial layer formation. At moderate seeding densities, hAEC production of human laminin was enhanced following serous seeding. Finally, inflammatory marker and pro-inflammatory cytokine expression decreased following long-term cell growth regardless of seeding side. This work demonstrates that at low and moderate seeding densities AR-BP sidedness significantly impacts endothelial cell growth, morphology, human laminin production, and inflammatory state. These findings suggest that ECM niche has a role in modulating response of repopulating recipient cells toward AR-BP scaffolds for vascular applications.
- Top Cited Papers
- 10 September 2019
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 13 (10) , 11008-11021
Collagenase Nanoparticles Enhance the Penetration of Drugs into Pancreatic Tumors
Overexpressed extracellular matrix (ECM) in pancreatic ductal adenocarcinoma (PDAC) limits drug penetration into the tumor and is associated with poor prognosis. Here, we demonstrate that a pretreatment based on a proteolytic-enzyme nanoparticle system, disassembles the dense PDAC collagen stroma, and increases drug penetration into the pancreatic tumor. More specifically, the collagozome, a 100-nm liposome encapsulating collagenase, was rationally designed to protect the collagenase from premature deactivation and prolonged its release rate at the target site. Collagen is the main component of the PDAC stroma, reaching 12.8±2.3%vol in diseased mice pancreases, compared to 1.4±0.4% in healthy mice. Upon intravenous injection of the collagozome, ~1% of the injected dose reached the pancreas over 8 hours, reducing the level of fibrotic tissue to 5.6±0.8%. The collagozome pretreatment allowed increased drug penetration into the pancreas and improved PDAC treatment. PDAC tumors, pretreated with the collagozome followed by paclitaxel micelles, were 87% smaller than tumors pretreated with empty liposomes followed by paclitaxel micelles. Interestingly, degrading the ECM did not increase the number of circulating tumor cells or metastasis. This strategy holds promise for degrading the extracellular stroma in other diseases as well, such as liver fibrosis, enhancing tissue permeability before drug administration.
- 10 September 2019
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 13 (10) , 11008-11021
Top Cited PapersCollagenase Nanoparticles Enhance the Penetration of Drugs into Pancreatic Tumors
Overexpressed extracellular matrix (ECM) in pancreatic ductal adenocarcinoma (PDAC) limits drug penetration into the tumor and is associated with poor prognosis. Here, we demonstrate that a pretreatment based on a proteolytic-enzyme nanoparticle system, disassembles the dense PDAC collagen stroma, and increases drug penetration into the pancreatic tumor. More specifically, the collagozome, a 100-nm liposome encapsulating collagenase, was rationally designed to protect the collagenase from premature deactivation and prolonged its release rate at the target site. Collagen is the main component of the PDAC stroma, reaching 12.8±2.3%vol in diseased mice pancreases, compared to 1.4±0.4% in healthy mice. Upon intravenous injection of the collagozome, ~1% of the injected dose reached the pancreas over 8 hours, reducing the level of fibrotic tissue to 5.6±0.8%. The collagozome pretreatment allowed increased drug penetration into the pancreas and improved PDAC treatment. PDAC tumors, pretreated with the collagozome followed by paclitaxel micelles, were 87% smaller than tumors pretreated with empty liposomes followed by paclitaxel micelles. Interestingly, degrading the ECM did not increase the number of circulating tumor cells or metastasis. This strategy holds promise for degrading the extracellular stroma in other diseases as well, such as liver fibrosis, enhancing tissue permeability before drug administration.
- 1 August 2019
- Published by Elsevier in Journal of Controlled Release
- Vol. 307, 331-341
Tailoring the lipid composition of nanoparticles modulates their cellular uptake and affects the viability of triple negative breast cancer cells
- 1 August 2019
- Published by Elsevier in Journal of Controlled Release
- Vol. 307, 331-341
Tailoring the lipid composition of nanoparticles modulates their cellular uptake and affects the viability of triple negative breast cancer cells